Creative Biosciences, a Chinese biotechnology start-up focusing on colorectal cancer detection, announced on Friday the completion of a RMB300 million (US$44.64 million) series B round of financing led by Boston-born investment firm IDG Capital and Chinese private equity firm CDH Investments.